Tags

Type your tag names separated by a space and hit enter

Multiple renin-angiotensin-aldosterone-blocking agents in heart failure: how much is too much?
Curr Heart Fail Rep 2009; 6(2):112-6CH

Abstract

Angiotensin-converting enzyme inhibitors (ACE-Is) and beta-adrenergic receptor blockers (BBs) have been effective in reducing cardiovascular morbidity and mortality in patients with heart failure (HF) and left ventricular systolic dysfunction (LVSD). Angiotensin receptor blockers and aldosterone blockers have also been shown to be effective. Although ACE-Is and BBs remain the therapies of choice for patients with HF-LVSD, many clinicians have attempted to further reduce patient morbidity and mortality by adding another inhibitor or blocker of the renin-angiotensin-aldosterone system to an ACE-I or BB. This article reviews the efficacy and safety of adding another renin-angiotensin-aldosterone system inhibitor or blocker to an ACE-I or an angiotensin receptor blocker plus a BB in patients with HF-LVSD.

Authors+Show Affiliations

University of Michigan School of Medicine, 1500 East Medical Center Drive, Ann Arbor, MI 48104, USA. bpitt@umich.edu

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

19486595

Citation

Pitt, Bertram. "Multiple Renin-angiotensin-aldosterone-blocking Agents in Heart Failure: How Much Is Too Much?" Current Heart Failure Reports, vol. 6, no. 2, 2009, pp. 112-6.
Pitt B. Multiple renin-angiotensin-aldosterone-blocking agents in heart failure: how much is too much? Curr Heart Fail Rep. 2009;6(2):112-6.
Pitt, B. (2009). Multiple renin-angiotensin-aldosterone-blocking agents in heart failure: how much is too much? Current Heart Failure Reports, 6(2), pp. 112-6.
Pitt B. Multiple Renin-angiotensin-aldosterone-blocking Agents in Heart Failure: How Much Is Too Much. Curr Heart Fail Rep. 2009;6(2):112-6. PubMed PMID: 19486595.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Multiple renin-angiotensin-aldosterone-blocking agents in heart failure: how much is too much? A1 - Pitt,Bertram, PY - 2009/6/3/entrez PY - 2009/6/3/pubmed PY - 2009/9/16/medline SP - 112 EP - 6 JF - Current heart failure reports JO - Curr Heart Fail Rep VL - 6 IS - 2 N2 - Angiotensin-converting enzyme inhibitors (ACE-Is) and beta-adrenergic receptor blockers (BBs) have been effective in reducing cardiovascular morbidity and mortality in patients with heart failure (HF) and left ventricular systolic dysfunction (LVSD). Angiotensin receptor blockers and aldosterone blockers have also been shown to be effective. Although ACE-Is and BBs remain the therapies of choice for patients with HF-LVSD, many clinicians have attempted to further reduce patient morbidity and mortality by adding another inhibitor or blocker of the renin-angiotensin-aldosterone system to an ACE-I or BB. This article reviews the efficacy and safety of adding another renin-angiotensin-aldosterone system inhibitor or blocker to an ACE-I or an angiotensin receptor blocker plus a BB in patients with HF-LVSD. SN - 1546-9549 UR - https://www.unboundmedicine.com/medline/citation/19486595/Multiple_renin_angiotensin_aldosterone_blocking_agents_in_heart_failure:_how_much_is_too_much L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=19486595.ui DB - PRIME DP - Unbound Medicine ER -